NRG Therapeutics
PrivateLast Round
Series B
Sep 8, 2025
Total Funding Raised
$95.4M
Company Overview
NRG Therapeutics is a neuroscience-focused drug discovery company developing treatments for neurodegenerative disorders such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). The company's approach is centered on leveraging breakthrough science in mitochondrial biology to create first-in-class, brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (mPTP). By inhibiting the mPTP, NRG aims to restore mitochondrial function, protect neurons, reduce neuroinflammation, and ultimately slow or halt the progression of these diseases. Founded in 2018, the company is backed by a syndicate of venture capital investors and has received grant funding from organizations like The Michael J. Fox Foundation. Its lead candidate, NRG5051, has completed pre-clinical studies and is expected to enter clinical trials in early 2026.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NRG Therapeutics Comps
Public and private peers based on sector, stage, and business model.
NRG Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2025 | ||||
| Grant | Oct 31, 2024 | ||||
| Grant | Sep 5, 2024 | ||||
| Grant | Feb 22, 2023 | ||||
| Series A | Nov 9, 2022 | ||||
Grant | May 30, 2022 |
NRG Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Omega Funds | Series B, Series A |
| SV Health Investors | Series B |
| Criteria Bio Ventures | Series B |
| Parkinson's UK | Series A, Seed, Series B |
| M Ventures | Series B |
| British Business Bank | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 23, 2025
Kathryn Oliver appointed to newly created role.
- Oct 23, 2025
David Brocklebank appointed to newly created role.
NRG Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NRG Therapeutics's valuation, stock price, and market status.
